Number
|
20
|
10
|
10
|
Sex (men/women)
|
14/6
|
9/1
|
5/5
|
Age at inclusion (years)
|
73 (57–84)
|
76 (70–84)
|
70 (57–84)
|
Diagnosis
|
MDS
|
9
|
5
|
4
|
AML
|
7
|
2
|
5
|
CMML
|
4
|
3
|
1
|
DNMTi treatment before inclusion (cycles)
|
0
|
11
|
5
|
6
|
1
|
3
|
1
|
2
|
2
|
3
|
2
|
1
|
3
|
1
|
1
|
0
|
4–7
|
2
|
1
|
1
|
IPSS-R score
|
5 (3.5–6.5)
|
4.5 (4–5.5)
|
5.5 (3.5–6.5)
|
Haemoglobin, g/dL
|
9.6 (7.1–14)
|
9.4 (7.1–14)
|
9.9 (7.6–12)
|
No. of blood transfusions in the study period
|
7 (0–33)
|
10 (0–33)
|
1 (0–18)
|
TET2 mutation, % of all (yes/no)
|
35% (7/13)
|
40% (4/6)
|
30% (3/7)
|
DNMT3A mutation, % of all (yes/no)
|
25% (5/15)
|
30% (3/7)
|
20% (2/8)
|
IDH2 mutation, % of all (yes/no)
|
10% (2/18)
|
20% (2/8)
|
0% (0/10)
|
Vitamin C, μmol/La
|
21 (5–73)
|
14 (5–37)
|
27 (7–73)
|
Iron, μmol/La
|
17 (2–33)
|
18 (2–33)
|
16 (5–32)
|
Transferrin, mg/dLa
|
184 (116–257)
|
169 (116–237)
|
199 (148–257)
|
Ferritin level, μg/La
|
1624 (95–6244)
|
1993 (444–6244)
|
1254 (95–3632)
|